Purpose: To explore the efficacy of sorafenib combined with radiofrequency ablation (RFA) in renal cancer and its effects on immunity and inflammation in patients. Methods: A total of 132 patients with advanced renal cancer treated in our hospital from January 2016 to January 2018 were randomly divided into control group and observation group. The patients in the control group were treated with sorafenib, while those in the observation group underwent RFA based on the treatment in the control group. The efficacy, immune function and changes in inflammatory factors in patients were compared between the two groups after treatment. Results: After treatment, the observation group had a significantly higher disease control rate (p<0.05), remarkably higher levels of cluster of differentiation 3(+) (CD3(+)) and CD4(+), and a notably lower level of CD8(+) than the control group. The increases in tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) as well as the decreases in interleukin-6 (IL-6) and C-reactive protein (CRP) were evidently greater in the observation group than in the control group (p <0.05). Finally, there was a markedly higher Karnofsky performance status (KPS) score in the observation group than in the control group (p <0.05). Conclusions: Sorafenib combined with RFA can significantly improve the therapeutic effect in renal cancer patients, with a high clinical therapeutic value, so it is worthy of clinical popularization and application.